ACTRN12611000799954已完成2 期
Fampridine treatment to improve fatigue in Multiple Sclerosis.
niveristy of New South Wales0 个研究点目标入组 25 人开始时间: 2011年7月29日最近更新:
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 发起方
- 入组人数
- 25
研究概览
简要总结
Fampridine treatment improved walking distance.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomised controlled trial
- 主要目的
- Treatment
- 盲法
- Blinded (masking used)
入排标准
- 年龄范围
- 18 Years 至 80 Years（—）
- 性别
- All
入选标准
- •Definitive diagnosis of MS
- •18-80 years of age.
- •Able to provide informed consent.
排除标准
- •History of seizures.
- •Current treatment with anticonvulsant medication.
- •Pregnancy or lactation. Contraception is required in pre-menopausal female patients.
- •History of moderate-severe renal impairment.
- •Presence of serious psychiatric disorder (e.g major depression, bipolar disorder)
- •Enrolled in another clinical trial involving an investigational agent.
- •Known allergy to pyridine-containing substances.
- •History of renal dysfunction, with eGFR <60 ml.
- •history of acute relapse within last 60 days
- •EDSS score >6.0
研究者
相似试验
尚未招募
2 期
Does Fampridine improve fatigue in patients with chronic inflammatory demyelinating polyneuropathy (CIDP).ACTRN12611000800921niveristy of New South Wales20
已完成
4 期
Resistance Training and Amino Pyridine in Multiple SclerosisMultiple SclerosisNCT02143167University of Southern Denmark40
已完成
不适用
Fampridine in MS Patients: A Cognition, Fatigue, Depression and Quality of Life AnalysisMultiple SclerosisNCT03164018Genesis Pharma CNS & Specialty111
已完成
不适用
Dalfampridine and Gait in Spinocerebellar AtaxiasSpinocerebellar Ataxias Type 1Spinocerebellar Ataxias Type 2Spinocerebellar Ataxias Type 3Spinocerebellar Ataxias Type 6NCT01811706University of Florida20
Unknown
不适用
Efficiency of 4-aminopyridin (Fampyra) on Gait, Vision, Cognition, Fatigue and Micturation in Patients With Multiple SclerosisEDSS 4-7Multiple SclerosisNCT01720849Vestre Viken Hospital Trust50